OncoMatch/Clinical Trials/NCT06595186
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Is NCT06595186 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including JK-1201I and Temozolomide (TMZ) for glioblastoma multiforme (gbm).
Treatment: JK-1201I · Temozolomide (TMZ) — This study was designed to evaluate the safety, tolerability, efficacy and pharmacokinetics of JK-1201I combined with adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and concomitant radio-chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: MGMT unmethylation
MGMT unmethylation (only for Dose Expansion Cohort)
Demographics
Prior therapy
Must have received: concurrent chemo-radiotherapy
Patients must finish concurrent chemo-radiotherapy (CCRT) no sooner than 4 weeks and no later than 6 weeks
Cannot have received: anti-tumor therapy except for concurrent chemo-radiotherapy (CCRT)
Patients who received anti-tumor therapy except for concurrent chemo-radiotherapy (CCRT)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06595186 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MGMT?
Yes, MGMT unmethylation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages